TABLE 1

Clinical information

Healthy controlMild asthmaModerate asthmaSevere asthma
Subjects22122022
Age years27.5 (24.3–34.8)25.5 (21.8–33.3)35.5 (23.5–47.3)52.5 (41.5–62.2)
Males/females14/87/58/128/14
Body mass index kg·m−224.2 (22.5–27.5)23.5 (22.8–25.6)25.1 (23.2–31.2)30.7 (27.4–35.8)
Disease control#22/0/0/00/5/6/10/4/13/30/0/2/20
Lung function
 FEV1 % predicted109 (106–113)87 (85,95)100 (89–108)62 (49–81)
 FEV1/FVC0.83 (0.80–0.88)0.74 (0.69–0.81)0.77 (0.70–0.82)0.64 (0.51–0.75)
Clinical
 Atopy0121715
 Atopy (positive skin test results)06 (4–7)3 (2–4)3 (0–5)
 Total IgE IU·mL−126 (11–58)198 (150–457)102 (38–183)105 (38–563)
Smoking status
 Never smoker20121718
 Former smoker (median pack years)2 (5.25)03 (2)3 (35)
 Current smoker (median pack years)0001 (49)
Treatment
 Inhaled steroids012022
 Dose equivalent µg BPDNANA400 (400–500)1600 (1280–2000)
 Oral corticosteroid maintenance0005
 Dose mg prednisolone·day−1NANANA15 (10–15)
 Long-acting β-agonist00922
 Leukotriene receptor antagonist00016
  • Data are presented as median (interquartile range) or number. FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; BPD: beclomethasone dipropionate equivalent; NA: not applicable. #Global Initiative for Asthma [1] level of control, presented as number of subjects with score of 0/1/2/3, where 0=no asthma, 1=controlled, 2=partly controlled, 3=uncontrolled.